LONDON (Reuters) - Long-term use of GlaxoSmithKline's Avandia and Takeda's <4502.T> Actos doubles the risk of bone fractures in women with type 2 diabetes, according to a study released on Wednesday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results